Perhaps this case has its specificity, but with the increasing number of ovarian cancer patients and the advancement and development of genetic testing technology, it is hoped that the report of this case can promote the search for more suitable targeted therapy groups, provide evidence for the use of targeted drugs in more ovarian cancer patients with EML4‐ALK fusion, and promote new ideas for the research of EML4‐ALK targets in ovarian cancer. The gene discussed is EML4; the disease is ovarian cancer.